|
⚲
|
| Keyboard |
| CPMG Inc
✚
|
|
|---|---|
| CRD # | 131417 |
| SEC # | 801-64945 |
| CIK # | 0001372218 |
| AUM | 855.8 M (2026-03-30) |
| Employees | 7 (29% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 214-871-6829 |
| Address | 4215 West Lovers Lane Dallas, TX 75209 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5: Fees and Compensation In consideration of our advisory services, we and/or certain of our affiliates may receive management fees, asset- based fees and/or performance-based fees or allocations (including carried interest distributions) with respect to the Funds. While our fees are described in detail in the applicable governing, account and/or offering documents, a brief summary of our fees is set forth below. Funds CPMG’s fee schedule is omitted because this brochure is only being delivered to qualified purchasers as defined in the Investment Company Act of 1940, as amended. Management fees generally are payable by investors quarterly, in advance, as of the beginning of each calendar quarter. Management fees are deducted directly from the capital account of each investor. In the event that a Fund is dissolved, an investor withdraws, or our advisory services are terminated prior to the end of any calendar quarter, then a proportionate amount of such management fee will be refunded to the applicable investor(s). In addition, one of our affiliates generally is entitled to receive a performance allocation of each qualified limited partner’s allocable share of net profits for the applicable performance period. Performance allocations are subject to a high-water mark limitation. Our advisory fees are generally not negotiable. Notwithstanding the foregoing, with respect to the Institutional Funds, we may be entitled to receive management fees and/or performance allocations pursuant to the terms and conditions set forth in the applicable governing documents. We negotiate fees with each applicable institutional investor on a case-by-case basis and such fees can be expected to vary. Performance allocations generally are calculated and accrued on a monthly basis. Performance allocations are crystallized and allocated generally as of the end of each fiscal year (and at such other times as set forth in the applicable partnership agreement). With respect to certain illiquid assets or securities (“Special Investments”), such allocations are not crystallized until the occurrence of a Special Investment “recognition event,” as such term is defined in the applicable partnership agreement. Performance allocations are allocated directly from the capital account of each applicable investor. CPMG and/or its affiliates have the right to not charge fees to an investor in a Fund, at our sole discretion. Advisory Accounts We generally receive a management fee, payable quarterly in either arrears or advance, equal to a percentage of the net asset value or the agreed upon targeted invested capital of each Advisory Account as of the applicable date of determination. Management fees generally are payable by Advisory Account clients quarterly in advance, as of the end of the prior calendar quarter. Management fees due and payable by an Advisory Account client may be paid by calling capital contributions for such purpose. For the avoidance of doubt, any client-directed positions are subject to the management fee. Performance results of client-directed positions are not considered as part of the performance fee allocation calculation. In addition, we or one of our affiliates may also be entitled to receive performance-based compensation equal to a percentage profits on distributions derived from the disposition of investments (following the return of contributed capital to the applicable Advisory Account client). Management fees and performance-based allocations or fees applicable with respect to each Advisory Account generally are expected to be negotiable on a case-by-case basis with clients. Performance-based fees or allocations generally will be due and payable to us promptly following the earlier of: (i) termination of the investment advisory agreement in accordance with its terms, (ii) a sale, exchange or other disposition that represents a complete divestiture of the securities position(s) in the Advisory Account or (iii) as the parties may otherwise mutually agree in writing. OTHER FEES AND EXPENSES Funds In addition to management fees, asset-based fees and/or performance allocations (as applicable), each Fund generally bears all costs and expenses relating to the Fund’s activities, including, but not limited to, (i) legal, auditing and accounting expenses (including the maintenance of books and records), (ii) costs for the preparation of the Fund’s financial statements, tax returns, and Schedule K-1s, (iii) expenses of the meetings of the limited partners, if any, (iv) interest expense, (v) research expenses, (vi) other expenses associated with the acquisition, holding and disposition of investments and (vii) extraordinary expenses, such as litigation. For the avoidance of doubt, certain Funds will, as applicable, bear the forgoing expenses incurred with respect to prospective investments (whether or not consummated), including “broken deal expenses” relating to an investment proposed to be allocated to the applicable Fund or Funds. Broken deal expenses will be allocated by CPMG on what we believe to be a fair and equitable basis to the applicable Fund or Funds. The Funds generally are responsible for and pay all brokerage and custodial fees and expenses. See Item 12 below. Advisory Accounts Advisory Accounts bear and/or otherwise share in various fees and expenses incurred by us and/or our affiliates in connection with the management of such accounts. Specifically, Advisory Account clients typically bear and are responsible for all costs and expenses directly related to the purchase, holding or sale of any portfolio investment(s) and any legal fees and costs that may be paid by the Advisory Account client in connection with any litigation or regulatory investigation. The specific fees and expenses borne by an Advisory Account typically are subject to negotiation and will vary from client to client. Advisory Account clients generally are responsible for and pay all ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7: Types of Clients We currently only provide investment advisory and supervisory services to private pooled investment vehicles and limited partnerships and managed accounts. We may provide advisory services to other types of clients in the future. Funds The minimum initial capital contribution required for an investor in each of the Funds is set forth in the applicable offering and/or governing documents. To invest in the Funds, investors generally must be, among other things, “accredited investors” as defined in Rule 501(a) of Regulation D under the U.S. Securities Act of 1933, as amended, and either “qualified clients” as such term is defined in Rule 205-3 under the Investment Advisers Act of 1940 (as amended, the “Advisers Act”), or “qualified purchasers” as such term is defined in Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended (the “Company Act”). Advisory Accounts Advisory Account clients are required to sign investment management agreements that, among other things, set forth the nature and scope of our investment management authority and the investment objectives, guidelines and restrictions applicable to the management of the Advisory Accounts. In addition, Advisory Account clients generally must meet certain net worth, net asset and/or other eligibility requirements imposed by various securities and commodities laws. In general, each Advisory Account client is required to be a “qualified client” as such term is defined in Rule 205-3 under the Advisers Act. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Inflection Point Acquisition Corp | 23.0 | ||
| Procept Biorobotics Corp | 10.7 | ||
| Instil Bio Inc | 3.4 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Aracari LP | [2025-03-28] | 25.5 M | 64.0 M |
| Filed 2025-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Gyrfalcon LP | [2025-03-28] | 39.7 M | 49.6 M |
| Filed 2025-11-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Icterine LP | [2025-03-28] | 20.6 M | 20.6 M |
| Filed 2026-02-19 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Manakin LP | [2023-08-24] | 26.2 M | 73.3 M |
| Filed 2026-02-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Motmot LP | [2023-08-24] | 36.7 M | 4.9 M |
| Filed 2025-05-15 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Oriole LP | 2023-03-31 | 12.7 M | |
| PE | Canary Partners LP | [2022-08-22] | 36.6 M | 65.4 M |
| Filed 2025-05-20 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Snowy Owl LP | [2022-05-25] | 35.4 M | 40.7 M |
| Filed 2026-01-30 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Cotinga LP | [2022-02-23] | 73.4 M | 90.3 M |
| Filed 2026-02-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Ibisbill LP | [2020-11-16] | 48.0 M | 4.7 M |
| Filed 2025-09-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 26 | 0.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 26 | 0.9 |
| By Discretionary | ||
| Discretionary | 26 | 0.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 0.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.8 | |
| Total | 26 | 0.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Bateman | Executive Officer | 40 | 4 | |
| CPMG Inc | Director, Executive Officer, Promoter | 40 | 4 | |
| R McGaughy | Executive Officer | 30 | 3 | |
| Anthony Miller | Executive Officer | 24 | 3 | |
| James Traweek | Director, Executive Officer | 22 | 3 | |
| Richard McGaughy | Director | 19 | 3 | |
| Ryan Schedler | Executive Officer | 8 | 3 | |
| Condire Investors LLC | Director | 6 | 3 | |
| Antal Desai | Executive Officer | 32 | 2 | |
| Adam Usdan | Executive Officer | 6 | 2 | |
| John Alderman | Executive Officer | 4 | 2 | |
| James Jr Traweek | Executive Officer | 2 | 1 | |
| Cardinal Partners 2000 LP | Promoter | 1 | 1 | |
| Moorhen LLC | Executive Officer | 1 | 1 | |
| Cardinal Partners LP | Promoter | 1 | 1 | |
| White Ibis GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001372218] | |
| 3 | [0001372218] | |
| 4 | [0001372218] | |
| SC 13D | [0001372218] | |
| SC 13G | [0001372218] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| CPMG Inc | Procept Biorobotics Corp | [2021-09-27] |
| CPMG Inc | Instil Bio Inc | [2021-04-01] |
| CPMG Inc | Golden Star Resources Ltd | [2019-02-14] |
| CPMG Inc | Apollo Endosurgery Inc | [2017-01-09] |
| CPMG Inc | Reata Pharmaceuticals Inc | [2016-06-06] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.4B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | FJGXH83P6BIM3DIKIU26 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| PROCEPT BioRobotics Corp | |
| CPMG Inc | |
| White Tailed Ptarmigan LP | |
| McGaughy R Kent Jr | |
| Reata Pharmaceuticals Inc | |
| Desai Antal Rohit | |
| Lpath Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
PROCEPT BioRobotics Corp PRCT
Common Stock
|
2024-05-03 | Other | 1,785,127 | $0.00 | |
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 442,560 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 748,253 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 431,155 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 109,415 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 37,909 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 334,740 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 307,776 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 34,897 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 44,200 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 5,464 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 137,962 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 282,246 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 113 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 116,512 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 1,251 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 993,929 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 114,946 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 1,490 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 150,186 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Bow Street LLC
✚
|
NY | 884.7 M |
|
Sandglass Capital Advisors LLC
✚
|
NY | 873.7 M |
|
TREO Asset Management LLC
✚
|
NY | 864.7 M |
|
Eagle's View Capital Management LLC
✚
|
NY | 860.5 M |
|
Arosa Capital Management LP
✚
|
FL | 856.6 M |
|
GFO Asset Management LLC
✚
|
FL | 856.1 M |
|
First Citizens Institutional Asset Management LLC
✚
|
NY | 829.2 M |
|
P2 Capital Partners LLC
✚
|
NY | 824.4 M |
|
MYDA Advisors LLC
✚
|
NY | 821.2 M |
|
Segra Capital Management LLC
✚
|
FL | 820.7 M |